Patent
Analgesic combination of oxycodone and meloxicam
| العنوان: | Analgesic combination of oxycodone and meloxicam |
|---|---|
| Patent Number: | 8,193,209 |
| تاريخ النشر: | June 05, 2012 |
| Appl. No: | 10/056347 |
| Application Filed: | January 25, 2002 |
| مستخلص: | Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and a dose oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a an oral dosage form comprising two analgesic compounds consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. |
| Inventors: | Burch, Ronald M. (Wilton, CT, US); Sackler, Richard S. (Greenwich, CT, US); Goldenheim, Paul D. (Wilton, CT, US) |
| Assignees: | Purdue Pharma L.P. (Stamford, CT, US) |
| Claim: | 1. A method of treating pain in humans consisting of orally administering to a human patient an oral dosage form consisting essentially of (a) two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of (i) a COX-2 inhibitor selected from meloxicam and/or at least one pharmaceutically acceptable salt thereof and (ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof; and (b) a sustained release carrier, wherein the amount of the COX-2 inhibitor administered is lower than the amount of the COX-2 inhibitor that would normally be required to produce analgesia when the COX-2 inhibitor is used alone; the oxycodone is in an amount from 2.5 mg to 800 mg; and the sustained release carrier is in an amount which causes a sustained release of the meloxicam and the oxycodone when the dosage form contacts gastrointestinal fluid and provides a therapeutic effect for about 12 hours or longer. |
| Claim: | 2. The method of claim 1 , wherein the oxycodone is present in the pharmaceutically acceptable salt form. |
| Claim: | 3. The method of claim 1 , wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a glyceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing. |
| Claim: | 4. The method of claim 1 , wherein said pain is cancer pain, post-surgical pain, low back and neck pain, dysmenorrheal, headache, toothache, pain from sprains and strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout, ankylosing spondylitis, bursitis, burns, injuries, influenza or other viral infections, or common cold. |
| Claim: | 5. A method of treating moderate to severe pain in humans consisting of orally administering to a human patient an oral dosage form consisting essentially of (a) two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of (i) a COX-2 inhibitor selected from meloxicam and/or at least one pharmaceutically acceptable salt thereof and (ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof; and (b) a sustained release carrier, wherein said meloxicam is in an immediate release form, said oxycodone is in a sustained release form, the sustained release form is in the form of melt-extruded multiparticulates, the sustained release carrier includes at least one hydrophobic material and is in an amount which causes a sustained release of the oxycodone for about 8 to 24 hours when the dosage form contacts gastrointestinal fluid, and the amount of the COX-2 inhibitor administered is lower than the amount of the COX-2 inhibitor that would normally be required to produce analgesia when the COX-2 inhibitor is used alone. |
| Claim: | 6. The method of claim 5 , wherein said sustained release carrier is selected from the group consisting of an alkylcellulose; a hydroxyalkylcellulose; an acrylic polymer; a fatty acid; a fatty alcohol; a gylceryl ester of fatty acids; a mineral oil or wax; a vegetable oil or wax; a polyalkylene glycol; shellac; zein; and mixtures of any of the foregoing. |
| Claim: | 7. The method of claim 5 , wherein said pain is cancer pain, post-surgical pain, low back and neck pain, dysmenorrheal, headache, toothache, pain from sprains and strains, myositis, neuralgia, synovitis, arthritis, degenerative joint diseases, gout, ankylosing spondylitis, bursitis, burns, injuries, influenza or other viral infections, or common cold. |
| Claim: | 8. The method of claim 5 , wherein said dosage form comprises particles, wherein said particles have diameter from about 0.1 mm to about 2.5 mm. |
| Claim: | 9. The method of claim 8 , wherein said particles have diameter from about 0.5 mm to about 2 mm. |
| Claim: | 10. The method of claim 5 , wherein the meloxicam is coated onto a tablet comprising oxycodone in sustained release form. |
| Claim: | 11. The method of claim 5 , with said sustained release carrier being (i) a sustained release coating; or (ii) incorporated into a matrix with said oxycodone. |
| Claim: | 12. The method of claim 5 , wherein said oral dosage form provides a therapeutic effect of said oxycodone for about 24 hours. |
| Claim: | 13. The method of claim 1 , wherein the oral dosage form is administered twice-a-day. |
| Claim: | 14. The method of claim 5 , wherein the oral dosage form is administered twice-a-day. |
| Claim: | 15. A method of treating pain in humans consisting of: (a) combining (i) COX-2 inhibitor selected from meloxicam or a pharmaceutically acceptable salt thereof, (ii) a sustained release material and (iii) oxycodone or a pharmaceutically acceptable salt thereof into a single oral dosage form, and (b) orally administering the dosage form to a human patient, wherein the sustained release carrier is in an affective amount to cause a sustained release of (i) the meloxicam and/or (ii) the oxycodone when the dosage form contacts gastrointestinal fluid, and the amount of the COX-2 inhibitor administered is lower than the amount of the COX-2 inhibitor that would normally be required to produce analgesia when the COX-2 inhibitor is used alone. |
| Claim: | 16. The method of claim 15 , wherein said oral dosage form comprises melt-extruded multiparticulates including at least one hydrophobic material and providing the sustained release for about 8 to 24 hours. |
| Claim: | 17. The method of claim 15 , wherein the dosage form is administered twice-a-day. |
| Claim: | 18. A method of treating pain in humans consisting of orally administering to a human patient an oral dosage form which combines (a) two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of (i) a COX-2 inhibitor selected from meloxicam or a pharmaceutically acceptable salt thereof and (ii) oxycodone or a pharmaceutically acceptable salt thereof; and (b) a sustained release carrier, wherein the sustained release carrier is in an amount which causes a sustained release of the meloxicam and/or the oxycodone when the dosage form contacts gastrointestinal fluid, and the amount of the COX-2 inhibitor administered is lower than the amount of the COX-2 inhibitor that would normally be required to produce analgesia when the COX-2 inhibitor is used alone. |
| Claim: | 19. The method of claim 18 , wherein said oral dosage form comprises melt-extruded multiparticulates including at least one hydrophobic material and providing the sustained release for about 8 to 24 hours. |
| Claim: | 20. The method of claim 18 , wherein the dosage form is administered twice-a-day. |
| Current U.S. Class: | 514/282 |
| Patent References Cited: | 3800041 March 1974 Miller et al. 4322427 March 1982 Buyinski et al. 4338324 July 1982 Gardocki 4404210 September 1983 Schmidt 4407804 October 1983 Schmidt 4407805 October 1983 Schmidt 4464376 August 1984 Sunshine et al. 4486436 December 1984 Sunshine et al. 4489080 December 1984 Lomen 4567183 January 1986 Sunshine et al. 4569937 February 1986 Baker et al. 4571400 February 1986 Arnold 4587252 May 1986 Arnold 4619934 October 1986 Sunshine et al. 4690927 September 1987 Voss et al. 4839176 June 1989 Pankhania et al. 4844907 July 1989 Elger et al. 4927854 May 1990 Sunshine et al. 4980170 December 1990 Schneider et al. 5164398 November 1992 Sims et al. 5190947 March 1993 Riess et al. 5240694 August 1993 Gwaltney, Jr. 5273760 December 1993 Oshlack et al. 5376384 December 1994 Eichel et al. 5409944 April 1995 Black et al. 5436265 July 1995 Black et al. 5458879 October 1995 Singh et al. 5472712 December 1995 Oshlack et al. 5474995 December 1995 Ducharme et al. 5510368 April 1996 Lau et al. 5516803 May 1996 Raffa 5521213 May 1996 Prasit et al. 5550142 August 1996 Ducharme et al. 5552422 September 1996 Gauthier et al. 5580578 December 1996 Oshlack et al. 5604253 February 1997 Lau et al. 5604260 February 1997 Guay et al. 5637320 June 1997 Bourke et al. 5639780 June 1997 Lau et al. 5691374 November 1997 Black et al. 5789413 August 1998 Black et al. 5834479 November 1998 Mayer et al. 5840731 November 1998 Mayer et al. 5843468 December 1998 Burkoth et al. 5859257 January 1999 Talley 5861419 January 1999 Dube et al. 5863922 January 1999 Mayer et al. 5869498 February 1999 Mayer et al. 6294195 September 2001 Oshlack et al. 0734275 April 1997 2023349 February 1991 2081604 May 1995 0068838 June 1982 0068838 June 1982 0274845 July 1988 0388125 September 1990 0649657 April 1995 0654263 May 1995 0654263 May 1995 WO 94/06416 December 1994 WO 97/12605 April 1997 9717978 May 1997 9725988 July 1997 WO 97/25988 July 1997 9732857 September 1997 9907413 February 1999 9932119 July 1999 |
| Other References: | Engelhardt et al., Inflamm. Res. 44:423-433 (1995). cited by examiner Engelhardt, Brit. J. Rheumatology 1996:35 (suppl. 1): 4-12. cited by examiner Distel et al., Brit. J. Rheumatology 1996:35 (suppl.1):68-77. cited by examiner Wojtulewski et al. Brit. J. Rheumatology 1996:(suppl. 1): 22-28. cited by examiner Furst, D. E. “Meloxicam: Selective COX-2 inhibition in clinical practice” Seminars in Arthritis and Rheumatism, Jun. 1997, 26(1), 21-27. cited by examiner Wikipedia, the Free Encyclopedia. TRPV1. Retrieved at on May 26, 2008 from http://en.wikipedia.org/wiki/TRPV1, pp. 1-7. cited by examiner Wikipedia, the Free Encyclopedia. Meloxicam. Retrieved at on May 26, 2008 from http://en.wikipedia.org/wiki/Meloxicam, pp. 1-3. cited by examiner Wikipedia, the Free Encyclopedia. Oxycodone. Retrieved at on May 26, 2008 from http://en.wikipedia.org/wiki/Oxycodone, pp. 1-10. cited by examiner See also Wikipedia, the Free Encyclopedia. Opioid. Retrieved at on May 26, 2008 from http://en.wikipedia.org/wiki/opioid, pp. 1-10. cited by examiner Pollack, A. “The Search for the Killer Painkiller” downloaded from http://opioids.com/pain/painkillers.html on May 26, 2008, pp. 1-12. cited by examiner Cole, S. “Phantom limb pain” downloaded from http://www.wellcome.ac.uk/en/pain/microsite/medicine2.html on May 26, 2008, pp. 1-4. cited by examiner National Institutes of Health U.S. Department of Health and Human Services, An update of NIH Pain Research and Related Program Initiatives, testimony delivered on Dec. 8, 2005 before Subcommitte on Health Committee on Energy and Commerce United States House of Representatives, pp. 1-21. cited by examiner Rittenberg, C. N., Positive thinking: an unfair burden for cancer patients? Support Care Cancer 1995, 3, 37-39, especially p. 38, col. 1, first full paragraph. cited by examiner Churchill et al (1996 Inflammopharmacology 4:125-135). cited by examiner Purdue Discovery Research, Department of Neuropharmacology Study Report “Assessment of the Effects of Combined Administration of Oxycodone and Cox II Inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain”; Jul. 28, 2003. cited by other The Merck Index, 12th edition, Merck & Co. Publishers, p. 1194 (1996). cited by other Goodman and Gillman's The Pharmacological Basis of Therapeutics, 6th edition, Macmillan Publishing Co., “Chapter 22: Opioid Analgesics and Antagonists,” p. 494-497, esp. Tables 22-1, p. 496 (1980). cited by other Rorarius et al. ,“Non-steroidal Anti-inflarnatory Drugs for Postoperative Pain Relief,” Current Opinion in Anesthesiology , 7:358-362 (1994). cited by other Friedel et al., “Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases,” Drugs vol. 45 (1):131-156, (1993). cited by other Eversmeyer et al., Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis, The American Journal of Medicine, vol. 95 (Suppl. 2A) pp. 10S-18S. cited by other Lipani, “Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials” Inflammopharmacology (1995) vol. 3(4) pp. 351-361. cited by other Tanaka et al., “Pharmacological Studies of the New Antiinflamatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one,” Arzneihm-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992). cited by other Swingle et al., “Preclinical Pharmacological Studies With Nimesulide,” Drugs Exptl. Clin. Res. vol. X (8-9) pp. 587-597. cited by other Rabasseda, “Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflamatory Drug,” Drugs of Today vol. 32, No. 5 (1996), p. 9. 365-384. cited by other Siebert et al., “Pharmacological and Biochemical Demonstration of the Role of Cycloocygenase 2 in Inflamation and Pain,” PNAS USA vo1.91 (Dec. 1994) pp. 12013-12-17. cited by other Richardson et al., “The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase,” Drug Safety vol. 15(4), pp. 249-260 (Oct. 1996). cited by other Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With an Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4.12, (1996). cited by other Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. British Journal of Anaesthesia 84 (2) 15-4 (2000). cited by other Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX-1 and COX-2 inhibitors in nerve-injured rats, J.M. Lashbrook, et al. Pain 82 (1) 65-72(1999). cited by other The Merck Index Results, “Nimesulide,” downloaded from http://themerckindex.cambridgesoft.com/TheMerckIndex/default.asp?; downloaded on Aug. 10, 2007. cited by other Translation of Office Action issued in connection with Russian Federation Patent Application No. 2000109552 (Nov. 1, 2001). cited by other STN: File Registry printout of Registry No. 162054-19-5 (Jun. 14, 2004 ). cited by other Abstract of Santos et al., “Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in Mice,” Inflammation Research (1998), 47(7) pp. 302-307, Chem. Abst. vol. 129 (Columbus, OH). cited by other Frölich, J.C., “A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes,” TiPS, Jan. 1997, vol. 18, pp. 30-34. cited by other Abstract of Ogino K. et al., “Evaluation of pharmacological profile of meloxicam as an anti-inflammatroy agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1,” Pharmacology 55(1):44-53, Jul. 1997. cited by other Abstract of Donnelly M.T. et al., Review article: “COX-II inhibitors—a new generation of safer NSAIDs?” Alimentary Pharmacology & Therapeutics 11(2):227-36, Apr. 1997. cited by other Abstract of Jouzeau J.Y. et al., “Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drus,” Drugs 53(4):563-82, Apr. 1997. cited by other Abstract of Dvornik D.M., “Tissue selective inhibition of prostaglandin biosynthesis by etodolac,” Journal of Rheumatology, Supplement 47:40-7, Feb. 1997. cited by other Abstract of Flower R.J., “New directions in cyclooxygenase research and their implications for NSAID-gastropathy,” Italian Journal of Gastroenterology, 28 Suppl. 4:23-7, Dec. 1996. cited by other Abstract of Kurumbail R.G. et al., “Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents,” Nature, 384(6610):644-8, Dec. 19-26, 1996. cited by other Abstract of Richardson C. et al, “The clinical implications of inhibition of the inducible form of cyclo-oxygenase,” Drug Safety, 15 (4): 249-60, Oct. 1996. cited by other Abstract of Pairet M. et al., “Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications,” Fundamental & Clinical Pharmacology 10(1):1-17, 1996. cited by other Abstract of Masferrer J.L. et al, “Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract,” Gastroenterology Clinics of North America 25(2):363-72, Jun. 1996. cited by other Abstract of Griswold D.E. et al.,“Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date,” Medicinal Research Reviews 16(2);181-206, Mar. 1996. cited by other Abstract of Hosie J. et al., “Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium,” British Journal of Rheumatology, 35 Suppl. 1:39-43, Apr. 1996. cited by other Abstract of Emery P., “Clinical implications of selective cycloxygenase-2 inhibiton,” Scandinavian Journal of Rheumatology—Supplement 102:23-8, 1996. cited by other Abstract of Vane J. R. et al, “New insights into the mode of action of anti-inflammatory drugs,” Inflammation Research 44(1):1-10, Jan. 1995. cited by other Abstract of Isakson P. et al., “Discovery of a better aspirin,” Advances in Prostaglandin, Thromboxane, & Leukotriene Research 23:49-54, 1995. cited by other Capasso, Anna et al. “Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum” European Journal of Pharmacology vol. 330 (1997), pp. 199-204. cited by other Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); Dec. 1, 1998; obtained from http://www.citizen.org/publications/print—release.cfm?ID=6653 on Oct. 28, 2008. cited by other NDA 020938 Approval letter and label Apr. 13, 2000; obtained from http://www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Medical Review, completed Aug. 31, 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Pharmacology Review(s), completed Sep. 17, 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Correspondence, 1998-1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Administrative Documents, 1998; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Chemistry Review(s), 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Microbiology Review(s) 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other NDA 20-938 Statistical Review(s) 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008. cited by other Therapeutics Initiative, Feb. 1995. cited by other Therapeutics Initiative, Jan. 1997. cited by other Therapeutics Initiative,Jan./Feb. 2001. cited by other Prescribing Points, vol. 8.4, Jun. 1999. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 09/154,354. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 10/033,055. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 10/056,475. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 10/056,348. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 10/057,630. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 10/057,631. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 10/057,632. cited by other Office Actions issued in connection with corresponding U.S. Appl. No. 11/698,394. cited by other Wollheim, F.A., “Current pharmacological treatment of osteoarthritis,” Drugs, vol. 52, Suppl. 3, p. 27-38, 1996. cited by other Capasso, Anna et al. “Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum” European Journal of Pharmacology vol. 330, pp. 199-204, 1997. cited by other Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) by NSAIDS: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., Inflammopharmacology 4; 61-70, (1996). cited by other Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. European J. Pharm 355 pp. 211-217, (1998). cited by other Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998). cited by other Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996). cited by other Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. and Applied Skin Phys. 11:273-278, (1998). cited by other Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cartiona Hay and Jacqueline de Belleroche, Neuro Report 8, 1249-1251, (1997). cited by other The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996). cited by other Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47:79-85, (1998). cited by other Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, vol. 16, No. 2, pp. 181-206, (1996). cited by other Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. vol. 12 pp. 1063-1073 (1998). cited by other Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With an Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996). cited by other Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998). cited by other Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996). cited by other Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Viscernonociception Induced by Phenylquinone, Hidenobu Kusuhara, et al. Prostaglandins 55: 43-49, (1998). cited by other Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dirig, et al. J. Pharmacol. and Experimental Therapeutics vol. 285, No. 3, pp. 1031-1038, 1998. cited by other Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. British Journal of Anaesthesia 84 (2) 151-4 (2000). cited by other Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. C.S. Wong et al., British Journal of Anaesthesia 85 (5) 747-51 (2000). cited by other Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. Eur. J. Pharmacology 387 (1) R1-R3 (2000). cited by other Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX-1 and COX -2 inhibitors in nerve-injured rats, J.M. Lashbrook, et al. Pain 82 (1) 65-72 (1999). cited by other Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones, Vaughn et al. British Journal of Pharmacology 123 (8) 1479-81 (1998). cited by other Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. Arzneim-Forsch./Drug Res. 46 (I) 57-63 (1996). cited by other Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G.K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp. 3-6, (1987). cited by other Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Ress. 47, Supplement 2 (1998). cited by other Rorarius et al., “Non-Steroidal Anti-Inflammatory Drugs for PostOperative Pain Relief,” Curr. Opin. in Anaesthesiology, 7, 358-362). (1994). cited by other Hanses et al. “Pharmacokinetics and Drug input Characteristics for a Disclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration,” Arzneim.-Forsch./Drug Res., 46(I), Nr. 1,57-63. (1996). cited by other Merck Index, Twelfth Edition, Merck & Co. Publishers, p. 1194. (1996). cited by other Goodman and Gillman's: Pharmaceutical Basis of Therapeutics, “Chapter 22: Opioid Analgesics and Antagonists”, MacMillan Publishing Co., Inc., pp. 494-497, esp. Table 22-1, p. 496. (1980). cited by other Degner, Frank, et al., “Efficacy and Tolerability of Meloxicam in an Observational, Controlled Cohort Study in Patients with Rheumatic Disease”, Clin Therapeutics (Nov. 2000) 22: 400-410. cited by other Lanes, Stephan et al., “Baseline Risk of Gastrointestinal Disorders Among New Users of Meloxicam, Ibuprofen, Diclofenac, Naaproxen and Indomethacin”, Pharmacoepidemiology and Drug Safety (2000) 9:113-117. cited by other Van Hecken, Anne, et al., “Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers”, J Clin Pharmacol (2000) 40: 1109-1120. cited by other Richy, F., et al., “Time dependent risk of gastrointestinal complications induced by non-steroid anti-inflammatory drug use: a consensus statement using a meta-analytic approach”, Ann Rhuem Dis (2004) 64:759-766. cited by other Dray et al. New Pharmacological Strategies for Pain Relief. Annual Review of Pharmacology &Toxicology, 36, pp. 253-280. (1996). cited by other Brasseur. L. Revue des therapeutiques pharmacolgoiques actuelles de la douleur. Drugs,53 Suppl 2, pp. 10-17. (1997). cited by other Rang et al. New molecules in analgesia. British Journal of Anesthesia, 75, pp. 145-156 (1995). cited by other Beaver, WT. Combination Analgesics. American Journal of Medicine, 77 (Suppl 3A), pp. 38-53. (1984). cited by other Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In Evaluation and Treatment of Chronic Pain, 2nd ed., William & Wilkins pp. 363-383. (1992). cited by other Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 9th Edition. McGraw-Hill, New York, pp. 535 and 551-552, 1996. cited by other Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain, 73, 3 pp. 401-406. (1997). cited by other Etches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. Anesthesia & Analgesia, 81 (6), pp. 1175-1180. (1995). cited by other Hodsman et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. Anaesthesia, 42(9), pp. 1005-1008. (1987). cited by other Kaasalainer et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. Pain, 70, 2-3, pp: 175-183. (1997). cited by other Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. Journal of Clinical Pharmacolology, 37 (10), pp. 908-915. (1997). cited by other Insel. Chapter 27: Analgesic-Antipyretic and Anti-inflammatory Agents. In Hardman, ed., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition. McGraw-Hill, New York, pp. 654-655. (1996). cited by other Polisson. Non-steroidal Anti-inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. The American Journal of Medicine, 100 (Suppl. 2A) , pp. 2A-31S-2A-36S. (1996). cited by other Vane, J. Towards a better aspirin. Nature, 367, pp. 215-216. (1994). cited by other Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX ‘Selectivity’. Journal of Clinical Rheumatology, 2 (3), pp. 135-140. (1996). cited by other Van Ryn et al. Selective cycloocygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. Expert Opinion on Investigational Drugs. pp. 609-614. (1997). cited by other Vane et al. New Insights Into the mode of action of anti-inflammatory drugs. Inflammation Research. 44, (No. 1), pp. 1-10 (1995). cited by other Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. British Journal of Rheumatology. 34, Abstract Suppl. 1, p. 48. (1995). Abstract. cited by other Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. Journal of Rheumatology. vol. 24, Suppl 49, pp. 20-24. (1997). cited by other Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. Neuropharmacology vol. 33,pp. 1609-1611. (1994). cited by other Donelly et al. COX-II Inhibitors—A new generation of safer NSAIDS? Alimentary Pharmacology and Therapeutics, 11, 2, pp. 227-236. (1997). cited by other Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. Gastroenterology, 112, 3, pp. 1000-1016. (1997). cited by other Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. J Rheumatoloty, 24, Suppl. 47, pp. 32-39. (1997). cited by other Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Muscoskeletal Disease: A Canadian Consensus. Canadian Medical Association Journal, 155, 1, pp. 77-88.(1996). cited by other Mehlisch et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. Journal of Clinical Pharmacology, 37, 9, 863. (1997). Abstract. cited by other Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointesinal Toxicity. Gut, 39, Suppl. 3, A151. (1996). Abstract. cited by other Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cylooxygenase-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). Journal of Medicinal Chemistry, 40(9), 1347-65. (1997). cited by other Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. Journal of Rheumatology, 24 Suppl 49, pp. 9-14. (1997). cited by other Litchtblau L., et al., “Pharmacologic Management of Cancer Pain in Rural Minnesota,” Journal of Pain and Symptom Management, vol. 12, No. 5, (1996), pp. 283-289. cited by other Pharmacovigilance Aug. 1994. cited by other Office Action issued on Dec. 22, 1999 in connection with U.S. Appl. No. 09/154,354. cited by other Office Action issued on Apr. 20, 2000 in connection with U.S. Appl. No. 09/154,354. cited by other Office Action issued on Jul. 28, 2006 in connection with U.S. Appl. No. 10/033,055. cited by other Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/033,055. cited by other Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/033,055. cited by other Office Action issued on Jul. 2, 2004 in connection with U.S. Appl. No. 10/033,055. cited by other Office Action issued on Sep. 7, 2004 in connection with U.S. Appl. No. 10/056,475. cited by other Office Action issued on Aug. 26, 2010 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Jun. 22, 2009 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Oct. 14, 2008 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Aug. 22, 2007 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Aug. 1, 2006 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Jul. 6, 2004 in connection with U.S. Appl. No. 10/056,348. cited by other Office Action issued on Jan. 7, 2011 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Feb. 4, 2009 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Sep. 21, 2007 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Jun. 19, 2006 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Sep. 29, 2005 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Sep. 7, 2004 in connection with U.S. Appl. No. 10/057,630. cited by other Office Action issued on Aug. 26, 2004 in connection with U.S. Appl. No. 10/057,631. cited by other Office Action issued on Nov. 24, 2009 in connection with U.S. Appl. No. 10/057,632. cited by other Office Action issued on Aug. 21, 2007 in connection with U.S. Appl. No. 10/057,632. cited by other Office Action issued on Aug. 10, 2006 in connection with U.S. Appl. No. 10/057,632. cited by other Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/057,632. cited by other Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/057,632. cited by other Office Action issued on Jun. 17, 2010 in connection with U.S. Appl. No. 11/698,394. cited by other Office Action issued on Aug. 19, 2009 in connection with U.S. Appl. No. 11/698,394. cited by other Office Action issued on Jan. 22, 2010 in connection with U.S. Appl. No. 11/698,394. cited by other Office Action issued on Nov. 15, 2010 in connection with U.S. Appl. No. 11/825,938. cited by other Office Action issued on Jun. 17, 2010 in connection with U.S. Appl. No. 11/825,938. cited by other Office Action issued on Feb. 19, 2010 in connection with U.S. Appl. No. 11/825,938. cited by other Office Action issued on Oct. 26, 2010 in connection with U.S. Appl. No. 10/057,632. cited by other Griswold, D.E., et al., “Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date,” Medicinal Research Reviews, vol. 16, No. 2, (1996), pp. 181-206. cited by other |
| Primary Examiner: | Gross, Christopher M. |
| Attorney, Agent or Firm: | Davidson, Davidson, & Kappel, LLC. |
| رقم الانضمام: | edspgr.08193209 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |